INmune Bio Inc (INMB)
11.06
+0.57
(+5.43%)
USD |
NASDAQ |
May 15, 14:43
INmune Bio Profit Margin (Quarterly): -78.75K% for March 31, 2024
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -78.75K% |
| December 31, 2023 | -30.03K% |
| September 30, 2023 | -19.91K% |
| June 30, 2023 | -14.13K% |
| March 31, 2023 | -17.20K% |
| December 31, 2022 | -6.01K% |
| September 30, 2022 | -7.88K% |
| Date | Value |
|---|---|
| June 30, 2022 | -42.74K% |
| March 31, 2022 | -4.23K% |
| December 31, 2021 | -5.93K% |
| September 30, 2021 | -67.56K% |
| June 30, 2021 | |
| March 31, 2021 | -113.9K% |
| December 31, 2020 | -29.13K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-113.9K%
Minimum
Mar 2021
-4.23K%
Maximum
Mar 2022
-33.65K%
Average
-19.91K%
Median
Sep 2023
Profit Margin (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 13.66% |
| Sarepta Therapeutics Inc | 8.74% |
| Dare Bioscience Inc | -279.8% |
| Zevra Therapeutics Inc | -485.3% |
| Kodiak Sciences Inc | -- |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -79.18% |
| Return on Assets | -55.60% |
| Return on Invested Capital | -62.23% |
| Operating Margin (Quarterly) | -78.69K% |
| Return on Net Operating Assets | -178.5% |